Sanofi-Aventis has had to take Inyx USA to court after it failed to
deliver on a contract manufacturing and supply agreement, a
situation that Aventis feared could "seriously harm its
interests". There may be important lessons...
The US Food and Drug Administration (FDA) has slammed
Sanofi-Aventis over its failure to act on known instances of fraud
during clinical trials of its antibiotic Ketek (telithromycin) -
accusations that the firm continues to deny.
Switzerland's Novartis has decided to withdraw from any
negotiations with Aventis over a possible merger, after official
discussions with the latter and fellow French-based company
Sanofi-Synthelabo got underway.
Switzerland's Novartis has confirmed that it is interested in
joining with Aventis, but will not proceed with a formal bid unless
the French government draws back from its hostile stance on a
link-up, reports Phil Taylor.
Sanofi-Synthelabo has strongly denied rumours that it is planning
to increase its offer for large pharmaceutical cousin Aventis,
despite the fact that the gap between its bid and Aventis'
valuation is widening by the day.
Aventis could hang on to its 15 per cent stake in chemicals company
Rhodia under the terms of a new agreement with the European
Commission. The company will instead sell off its 49 per cent stake
in Wacker Chemie over the next several...
Sanofi's hostile bid for larger French rival Aventis may have been
rejected, but there are a number of arguments in favour of a link,
according to analyst Nicole Lamble at market research firm